Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 406

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 406
---
 |   |     | $ |   214.40 |   |     | $ |    16.00 |   |
| As at 1 January 2023                     |     |   |          – |   |     |   |        – |   |     |   |        – |   |     |   |        – |   |
| Issued:                                  |     |   |            |   |     |   |          |   |     |   |          |   |     |   |          |   |
| Private Placement February 2023          |     |   |    155,461 |   |     |   |   32,327 |   |     |   |   48,491 |   |     |   |        – |   |
| Registered Direct Offering May 2023      |     |   |          – |   |     |   |        – |   |     |   |        – |   |     |   |  415,043 |   |
| Registered Offering December 2023        |     |   |  1,911,176 |   |     |   |        – |   |     |   |        – |   |     |   |        – |   |
| Adhera Assignment and Exchange Agreement |     |   |    899,642 |   |     |   |        – |   |     |   |        – |   |     |   |        – |   |
| Exercised                                |     |   |   (155,461 | ) |     |   |  (32,327 | ) |     |   |  (48,491 | ) |     |   | (415,043 | ) |
| As at 31 December 2023                   |     |   |  2,810,818 |   |     |   |        – |   |     |   |        – |   |     |   |        – |   |

The Series A, Series
B and Series C warrants are exercisable on an ‘alternative cashless basis’ effectively allowing the holders to exercise for
nil consideration.

Numbers of shares and
share options/ warrants and related exercise/issue prices are after the impact of the 24 March 2023 share consolidation, ADS ratio changes
on 24 March 2023 and 5 July 2023.

In accordance with the
Articles of Association for the Company adopted